Clinical efficacy of combined treatment with entecavir and adefovir dipivoxil for lamivudine-resistant chronic hepatitis B

Bao Jun; Liang JunCai; Gong Li; Chen XiaoXiao

doi:10.3969/j.issn.1001-5256.2014.10.014

Issue 10

Oct. 2014

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2014 > 30(10): 1031-1034

PDF( 1355 KB)

Clinical efficacy of combined treatment with entecavir and adefovir dipivoxil for lamivudine-resistant chronic hepatitis B

DOI: 10.3969/j.issn.1001-5256.2014.10.014

Department of Gastroenterology, Jiangsu Province Geriatric Hospital

Received Date: 2014-07-28
Published Date: 2014-10-20

Abstract

Abstract

Objective To evaluate the efficacy and safety of the combined therapy with entecavir ( ETV) and adefovir dipivoxil ( ADV) in patients with lamivudine ( LAM) -resistant chronic hepatitis B ( CHB) . Methods A total of 45 patients who were diagnosed with LAM-resistant CHB and admitted to the Kunshan People's Hospital from May 2011 to May 2013 were recruited in this study and randomly divided to two groups. The treatment group included 23 CHB patients who received the combined therapy with ETV and ADV. The control group included 22 CHB patients who received the combined therapy with LAM and ADV. The changes in levels of HBV DNA, alanine aminotransferase ( ALT) , aspartate aminotransferase ( AST) , total bilirubin ( TBil) , albumin ( Alb) , and HBV serum markers before and after 4, 12, 24, and 48 weeks of treatment, as well as the rate of mutations other than that at rtM204 I after 48 weeks of treatment, were measured in both groups. Comparison of continuous data between groups was made by t test, and comparison of categorical data by fourfold table chi-square test. Results The levels of ALT and AST in the treatment group were significantly lower than those in the control group after 4 and 12 weeks of treatment ( t = 3. 124, 5. 271, 4. 476, 5. 125, all P < 0. 01) , as well as 24 and 48 weeks of treatment ( t = 2. 240, 2. 307, 2. 886, 2. 908, all P < 0. 05) . The serum HBV DNA clearance rates in the treatment group after 4, 12, 24, and 48 weeks of treatment were73. 9%, 86. 8%, 95. 7%, and 100%, respectively, all of which were significantly higher than those in the control group ( χ2= 11. 79, 5. 75, 10. 29, 5. 89, respectively, all P < 0. 05) . However, there was no significant difference in the HBeAg seroconversion rate among HBeAg-positive patients between the two groups. No mutations other than that at rtM204 I were found in the treatment group, while four new mutations were detected in the control group ( χ2= 4. 59, P < 0. 05) . Conclusion The combined therapy with ETV and ADV has good therapeutic effect in treating LAM-resistant CHB patients, and the clinical application is highly recommended.
- hepatitis B, chronic,
- ETV,
- ADV,
- LAM,
- combination therapy,
- drug resistance

FullText(HTML)

References(17)

References

[1]GANEM D, PRINCE AM.Hepatitis B virus infection--natural history and clinical consequences[J].N Engl J Med, 2004, 350 (11) :1118-1129.

[2]ZHANG XH, LI ZP.Changes in serum complement components after 48 weeks of entecavir treatment in hepatitis B cirrhosis patients[J].J Clin Hepatol, 2013, 29 (5) :508-511. (in Chinese) 张雪华, 李仲平.恩替卡韦治疗乙型肝炎肝硬化患者48周前后血清补体的变化[J].临床肝胆病杂志, 2013, 29 (5) :508-511.

[3]LEUNG NW, LAI CL, CHANG TT, et al.Extended lamivudine treatment in patients with chronic hepatitis B enchances hepatitis B e antigen seroconversion rates:results after three years of therapy[J].Hepatology, 2001, 33 (6) :1527-1532.

[4]LAI CL, GANE E, LIAW YF, et al.Telbivudine versus lamivudine in patients with chronic hepatitis B[J].N Engl J Med, 2007, 357 (25) :2576-2588.

[5]CHANG TT, GISH RG, de MAN R, et al.A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B[J].N Engl J Med, 2006, 354 (10) :1001-1010.

[6]LIM YS, HAN S, HEO NY, et al.Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine[J].Gastroenterology, 2014, 147 (1) :152-161.

[7]ZOULIM F, LOCARNINI S.Management of treatment failure in chronic hepatitis B[J].J Hepatol, 2012, 56:s112-s122.

[8] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B (2010 version) [J].J Clin Hepatol, 2011, 27 (1) :Ⅰ-ⅩⅥ. (in Chinese) 中华医学会肝病分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2010年版) [J].临床肝胆病杂志, 2011, 27 (1) :Ⅰ-ⅩⅥ.

[9]LAMPERTICO P, VIGANM, MANENTI E, et al.Low resistance to adefovir combined with lamivudine:a 3-year study of 145 lamivudine-resistant hepatitis B patients[J].Gastroenterology, 2007, 133 (5) :1445-1451.

[10]RYU HJ, LEE JM, AHN SH, et al.Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B[J].J Med Virol, 2010, 82 (11) :1843-1849.

[11]LEE YB, LEE JH, CHOI WM, et al.Efficacy of adefovir-based combination therapy for patients with lamivudine-and entecavir-resistant chronic hepatitis B virus infection[J].Antimicrob Agents Chemother, 2013, 57 (12) :6325-6332.

[12] LEE YS, SUH DJ, LIM YS, et al.Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after48 weeks of adefovir dipivoxil monotherapy[J].Hepatology, 2006, 43 (6) :1385-1391.

[13]SUZUKI Y, SUZUKI F, KAWAMURA Y, et al.Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years:Histological improvement or entecavir resistance[J].J Gastroenterol Hepatol, 2009, 24 (3) :429-435.

[14]CHO SW, KOH KH, CHEONG JY, et al.Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance[J].J Viral Hepat, 2010, 17 (3) :171-177.

[15]DELANEY WE 4th, YANG H, MILLER MD, et al.Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro[J].Antimicrob Agents Chemother, 2004, 48 (10) :3702-3710.

[16]ZENG T, XU H, LIU JY, et al.Entecavir plus adefovir combination therapy versus lamivudine add-on adefovir for lamivudine-resistant chronic hepatitis B:a meta-analysis[J].J Clin Pharmacol, 2014, 54 (9) :959-967.

[17]KE W, LIU L, ZHANG C, et al.Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection:a systematic review and meta-analysis[J].PLoS One, 2014, 9 (6) :e98476.

Relative Articles

[1]	Li Na, Gou Wei, Cui WeiLi. Efficacy of telbivudine combined with adefovir dipivoxil and pegylated interferon combined with entecavir as antiviral therapy for chronic hepatitis B: a comparative analysis[J]. Journal of Clinical Hepatology, 2016, 32(9): 1714-1716. doi: 10.3969/j.issn.1001-5256.2016.09.015
[2]	Yang DongQiang, Chen Fang, Kang Yi, Ding GangQiang, Xiao ErHui, Peng Zhen, Shang Jia. Genotypes and resistance loci in patients with chronic hepatitis B achieving virologic breakthrough in treatment with lamivudine combined with adefovir after developing drug resistance in treatment with lamivudine alone[J]. Journal of Clinical Hepatology, 2016, 32(3): 480-483. doi: 10.3969/j.issn.1001-5256.2016.03.016
[3]	Zhang Wen, Yu JianGuo, Zhu GuiZhong, Zhao ZhanDong, Wang XiaoWei. Clinical efficacy of entecavir combined with adefovir in chronic hepatitis B patients with high viral load[J]. Journal of Clinical Hepatology, 2014, 30(11): 1169-1172. doi: 10.3969/j.issn.1001-5256.2014.11.019
[4]	Huang MeiJin, Tan HouJi, He YanZhuan, Huang QiWen, Zhou YaoNan, Qiu HaiXian. Forty-eight-week efficacy of adefovir dipivoxil alone versus combined with lamivudine in treatment of lamivudine-resistant HBeAg-positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2014, 30(7): 636-638. doi: 10.3969/j.issn.1001-5256.2014.07.015
[5]	Ruan BingWei, Lu XiaoJu, Lin YanMing, Chen RongCe, Chen XinZhi, Ceng GuangZhong, Liu YanPing. Evaluation of adverse reactions induced by adefovir dipivoxil in 85 chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2013, 29(2): 104-106.
[6]	Ma YanHong. Clinical effect of initial combination therapy with lamivudine plus adefovir dipivoxil in 48-week treatment of HBeAg-positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2013, 29(8): 631-632. doi: 10.3969/j.issn.1001-5256.2013.08.020
[7]	Yan HaiMing, Chen JianHua, Ye YiNong, Long Hui, Wang XiangHuai. Clinical effects of lamivudine combined with adefovir dipivoxil and entecavir alone in 48-week treatment of HBeAg-positive chronic hepatitis B:preliminary comparative study[J]. Journal of Clinical Hepatology, 2013, 29(7): 508-511. doi: 1001-5256 (2013) 07-0508-04
[8]	Song MinNing, Huang WenQi, Min Feng, Hong MeiZhu, Fan RongHua, Wu WeiBing, Zhang Li. The efficacy of 3 years adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance[J]. Journal of Clinical Hepatology, 2012, 28(1): 29-32.
[9]	Liu LongGen, Ye ChunYan, Tong XueCheng. Maintenance of negative HBV DNA in patients with chronic hepatitis B during 96 weeks followup with active replacement of Adefovir dipivoxil with Lamivudine[J]. Journal of Clinical Hepatology, 2011, 27(3): 292-294.
[10]	Geng JianZhang, Fan XiaoHong, Lu HaiYing, Li Jing, Tian XiuLan, Xu XiaoYuan. The evaluation of de novo combination of antiviral treatment to hepatitis B patients with decompensated cirrhosis[J]. Journal of Clinical Hepatology, 2011, 27(8): 837-839+843.
[11]	Gu QiangYe, Li Qin, Ge XiuLin. Observation of long-term efficacy of different treatment protocol of Adefovir dipivoxil in chronic hepatitis B patients with Lamivudine-resistance[J]. Journal of Clinical Hepatology, 2011, 27(4): 411-413.
[12]	Song MinNing, Zhang Li, Huang WenQi, Min Feng. Treatment of chronic hepatitis B with Adefovir dipivoxil:A 3 years observation of clinical efficacy and drug resistance[J]. Journal of Clinical Hepatology, 2010, 26(1): 22-24.
[13]	Yang YaFang, Yang XiaoPing, Dong JianGuo, Wang ZhiGang, Liu YanPing, Zhao TieJun, Gao Feng. Analysis of short-term efficacy of entecavir and adefovir dipivoxil in the treatment of HBeAg-positive chronic hepatitis B [J]. Journal of Clinical Hepatology, 2010, 26(3): 326-327.
[14]	Zhu FeiYan. The clinical effect Adefovir dipivoxil in Lamivudine resistant HBeAg positive chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2010, 26(5): 517-518.
[19]	Cao TianGao, Li JingNan, Shi YunZhen, Li ChaoXia. The clinical study of foscarnet sodium combined with adefovir dipivoxil for lamivudine-resistant patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2008, 24(4): 248-250.

Supplements(0)

Cited By

Cited by

Periodical cited type(11)

1.	肖春桃，李贤秋，甘佩灵，潘潇，周贤. 基于倾向性评分匹配分析门静脉血栓对肝硬化患者预后的影响. 临床肝胆病杂志. 2021(08): 1829-1835 . 本站查看
2.	王彤，牛焕章，杜廷伟，魏乐群. 乙型肝炎肝硬化患者门静脉血栓发生的影响因素及抗凝治疗效果研究. 深圳中西医结合杂志. 2021(17): 134-136 .
3.	姜炅，袁佳，史海涛，戴社教. 血清ALT、AST联合NFS评分对非酒精性脂肪性肝硬化患者食管胃底静脉曲张严重程度的评估价值. 中西医结合肝病杂志. 2020(04): 314-317 .
4.	李英，高磊，胡扬喜，胡德升. 低分子肝素钙联合右旋糖酐在肝硬化门静脉高压症术后静脉血栓形成预防中的应用. 肝脏. 2019(07): 788-790 .
5.	吕靖，董思思，顾宏图，赵长青，刘成海. 肝硬化并发门静脉血栓的危险因素及中医证候特点. 临床肝胆病杂志. 2019(10): 2210-2213 . 本站查看
6.	陈仙艳. 肝硬化合并上消化道出血患者门静脉血栓形成危险因素分析与护理. 护理实践与研究. 2019(18): 13-15 .
7.	牟思玉，杨哲，吴力群，邱轩，郭珈铭. 肝硬化门静脉高压脾切除术后门静脉血栓形成的预测因素分析. 临床肝胆病杂志. 2018(01): 106-111 . 本站查看
8.	张津瑜，陈文显，沈华，王雁，张国雷，慎华平，吴万波，魏云海. 大鼠门静脉系统血栓形成模型的建立和观察. 中国普通外科杂志. 2018(06): 724-731 .
9.	邢文立，李谦. 重症监护病房肝病患者的血栓预防与出血控制. 临床肝胆病杂志. 2018(10): 2237-2240 . 本站查看
10.	李志州，向俊峰，周威，唐亮. 探讨门脉高压及外伤性脾破裂行脾切除术后血小板升高及门静脉血栓形成情况. 肝胆外科杂志. 2018(04): 280-282 .
11.	王士浩，张宏伟. 肝硬化合并门静脉血栓形成危险因素的病例对照研究. 中国中西医结合消化杂志. 2017(11): 867-870 .

Other cited types(12)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (3700) PDF downloads(612)

Clinical efficacy of combined treatment with entecavir and adefovir dipivoxil for lamivudine-resistant chronic hepatitis B

DOI: 10.3969/j.issn.1001-5256.2014.10.014